A

AC Camargo Cancer Center | International Research Center (CIPE)

Research site

(Unclaimed)

Location

R. Tagua, 440, Liberdade, Sao Paulo, Sao Paulo, Brazil

Site insights

Top conditions

Top treatments

Gemcitabine

TAR-200

Bemarituzumab

Prednisone

Doxorubicin

Vincristine

Cisplatin

Pembrolizumab

Cyclophosphamide

Elotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

This study is researching an experimental drug called linvoseltamab, also called REGN5458.Linvoseltamab has previously been studied by itself (withou...

Enrolling

Relapsed Refractory Multiple Myeloma (RRMM)

Drug: Pomalidomide

Drug: Linvoseltamab

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling

Follicular Lymphoma (FL)

Drug: Odronextamab

Drug: Rituximab

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab